Working… Menu

A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01062620
Recruitment Status : Completed
First Posted : February 4, 2010
Last Update Posted : September 15, 2011
Information provided by:
Axelar AB